English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Dopaminergic and noradrenergic contributions to functionality in ADHD: The role of methylphenidate

Engert, V., & Pruessner, J. C. (2008). Dopaminergic and noradrenergic contributions to functionality in ADHD: The role of methylphenidate. Current Neuropharmacology, 6(4), 322-328. doi:10.2174/157015908787386069.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/21.11116/0000-0005-B18D-4 Version Permalink: http://hdl.handle.net/21.11116/0000-0005-B687-5
Genre: Journal Article

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Engert, Veronika1, Author              
Pruessner, Jens C. 1, Author
Affiliations:
1External Organizations, ou_persistent22              

Content

show
hide
Free keywords: ADHD; Methylphenidate; Dopamine; Noradrenaline; Subcortical; Prefrontal
 Abstract: Attention Deficit Hyperactivity Disorder (ADHD) is a childhood psychiatric condition characterized by severe impulsiveness, inattention and overactivity. Methylphenidate (MPH), a psychostimulant affecting both the dopaminergic and the noradrenergic systems, is one of the most frequently prescribed treatments for ADHD. Despite the widespread use of MPH and its proven effectiveness, its precise neurochemical mechanisms of action are under debate. For the most part, MPH’s influence on subcortical dopamine neurotransmission is thought to play a crucial role in its behavioral and cognitive effects. In their hypothesis of biphasic MPH action, Seeman and Madras suggest that therapeutic doses of MPH elevate tonic dopamine while inhibiting phasic transmitter release in subcortical structures, leading to reduced postsynaptic receptor stimulation and psychomotor activation in response to salient stimuli. Volkow and colleagues suggest that by amplifying a weak striatal dopamine signal, MPH increases the perception of a stimulus or task as salient. The enhanced interest for the task is thought to increase attention and improve performance. Recent animal studies have however shown that when administered at doses producing clinically relevant drug plasma levels and enhancing cognitive function, MPH preferentially activates dopamine and noradrenaline efflux within the prefrontal cortex relative to the subcortical structures. Overall, we suggest that the delineated theories of MPH therapeutic action should not be discussed as exclusive. Studies are outlined that allow integrating the different findings and models.

Details

show
hide
Language(s): eng - English
 Dates: 2008-07-182008-05-152008-08-042008-122008-12
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Method: -
 Identifiers: DOI: 10.2174/157015908787386069
PMID: 19587853
PMC: PMC2701285
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Current Neuropharmacology
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Hilversum : Bentham Science
Pages: - Volume / Issue: 6 (4) Sequence Number: - Start / End Page: 322 - 328 Identifier: ISSN: 1875-6190
CoNE: https://pure.mpg.de/cone/journals/resource/1875-6190